Abstract: Closed-loop administration devices for general anaesthesia have become a common subject of clinical research over the last decade and appear more and more acceptable in clinical practice. They encompass various therapeutic needs of the anesthetized patient, e. g. fluid administration, hypnotic and analgesic drug administration, myorelaxation. Multiple clinical trials involving closed-loop devices have underscored their safety, but data concerning their clinical benefit to the patient are still lacking. As the marketing of various devices increases, clinicians need to understand how comparisons between these devices can be made: the measure of performance error and wobble are technical but have also a clinical meaning, to which clinical outcomes can be added, such as drug consumption and maintenance of hemodynamic parameters (e. g. heart rate and blood pressure) within predefined ranges. Clinicians using closed-loop devices need especially to understand how various physiological signals lead to specific drug adaptations, which means that they switch from decision making to supervision of general anaesthesia.
Introduction
Closed-loop administration devices for general anaesthesia (GA) have become a common subject of clinical research over the last decade and appear more and more acceptable in clinical practice [1] . As a rule, closed-loops require a technical architecture that enables a specific algorithm to infer a therapeutic administration from one or more signals. Simple closed-loops exist in our familiar environment such as central heating machines whose activation is activated/deactivated by room temperature. Adapting therapeutic targets to physiological signals has been applied to several domains of anaesthesia and intensive care: fluid administration [2] [3] [4] , mechanical ventilation [5] , general anaesthesia [6] [7] [8] [9] , hyperglycemia [10] . General anaesthesia results from the combination of hypnotic and analgesic drugs, sometimes associated to myorelaxants, in order to produce amnesia, analgesia and immobility [11, 12] . Drugs used for induction and maintenance of GA have well known side effects such as hypotension, mainly related to their influence on the cardio-vascular system as they interfere with the autonomous nervous system (ANS), mainly in its sympathetic and parasympathetic (pS) parts. This explains partly how the safety of GA has increased since monitoring has become mandatory: signals related to the hemodynamics of the patient undergoing general anaesthesia include electrocardiography (ECG), non-invasive blood pressure (NIBP) and in some cases invasive or non-invasive continuous blood pressure measurements [13] . Variations of heart rate (HR) and blood pressure (BP), even if absolutely not sensitive nor specific, have been used by anesthesiologists for decades for assessing individual needs for intravascular volume administration, analgesic drugs, hypnotic drugs, and vasoactive drugs. Some more specific informations have been derived from these simplistic signals in order to more specifically predict a state of pre-load dependency, like the deltaPP index which is derived from the continuous blood pressure signal [14] and the variations in the amplitude of the non-invasive photoplethysmographic (SpO2) signal [15] .
Sensors and devices enabling closed-loop drug administration Monitoring depth of hypnosis
Monitors of the depth of hypnosis are used routinely during GA in order to personalize the administration of hypnotic drugs and avoid deep sedation or under dosage which can lead to conscious awareness. They mainly record a simplified electroencephalographic (EEG) signal which is processed in real time and leads to the continuous display of several values related to the brain function. One of the first EEG monitoring systems is the BiSpectral Index ® (Aspect Medical Systems, MA). The simplified surface EEG signal recorded with three to four frontal electrodes is decomposed into several sinus waves ( Figure 1 ).
The computation of the BiSpectral Index (BIS) relies on the analysis of the power spectrum the EEG signal and the synchronization of the multiple sinus waves, and produces a numerical value ranging from 0 to 100 which has been associated with deepening states of sedation from 80 (light sedation) down to general anaesthesia when the BIS is between 40 
Monitoring myorelaxation
Myorelaxant are widely used during GA in order to enable surgery and/or facilitate tracheal intubation. The pharmacokinetics of myorelaxants are compatible with intermittent boluses as well as with continuous administration. Monitoring myorelaxation has long been shown to be a factor of quality of anaesthesia as it enables adequate titration during surgery and security when weaning ventilation and extubating patients [16] [17] [18] . Myolexation monitoring relies on electrical stimulations of the ulnar nerve at the wrist or of the palpebral orbicular muscle: results are expressed as a percentage of muscular response, with known thresholds (targets) for surgery and extubation [19] . In current practice, various types of electrical stimulations can be used. One of them is called "train of four (TOF)": four electrical stimulations, T1 to T4, separated by 0.5 s are applied to the ulnar nerve at the wrist. A control measure is usually made under GA before the myorelaxant is administered, after which the muscle response at T4 decreases and can be followed during surgery in order to keep myorelaxation compatible with surgery. At the end of surgery, a T4/T1 ratio over 90 % expresses the absence of residual neuromuscular blockade, thus making weaning of the mechanical ventilation possible with optimal security. Other types of electrical stimulation include the twitch, post tetanic count and double burst stimulation, but are less likely than TOF to help close the loop on myorelaxing drugs during GA.
Monitoring analgesia
Analgesic drugs and opioid in particular have been at the core of medical care during surgical and painful procedures for several decades [20] , even if they do not appear namely in some definitions of anaesthesia where immobility and amnesia are underlined [11] . Some authors underline that monitoring the balance between antinociception and nociception is the way to administer better (more personalized) analgesia [21] . The emergence of new anti-nociceptive drugs in recent years has shown the benefits of combining opioid and non-opioid drugs in order to decrease opioid side effects [22] [23] [24] [25] [26] [27] [28] [29] .
In clinical practice, anesthesiologists adjust analgesic drugs infusion regarding changes in HR and BP but these parameters are neither sensitive nor specific of the nociception-analgesia imbalance. What is more, target values for BP and HR depend on several conditions like patient's ASA score, age, type of surgery, comorbidities such as vascular and heart diseases. Based on variations in HR and BP, Hemmerling et al. developed the Analgoscore TM [30] , which is determined by measuring the percentage of variations in mean arterial pressure and heart rate ( Interestingly, side effects associated with the administration of opioids seem to play a major role in the result of the Analgoscore, with overdose associated with hypotension and bradycardia and under dose associated with tachycardia and elevated blood pressure.
The Analgesia Nociception Index (ANI) monitor (MDMS, Loos, France) enables a real time analysis of the pS activity based on the ECG signal [31] , by detecting each R peak and establishing the RR interval series over time (Figure 2) .
The RR series is normalized and band pass filtered between 0.15 and 0.4 Hz in order to keep only high frequency oscillations, which are under the influence of pS activity only [32] . Local minima and maxima of the remaining signal are detected and the area between the lower and upper envelopes is divided into four subareas A1, A2, A3 and A4 ( Figure 3 ). AUCmin is defined as the minimum of the 4 subareas.
ANI is then computed as: ANI = 100 × ða × AUCmin + bÞ=12.8 Table 1 : Decision matrix for Analgoscore TM measurement. where a = 5.1 and b = 1.2 have been determined on a set of patients in order to keep the visual coherence between the visual effect of respiration on the RR series and the quantitative importance of pS tone. ANI values decrease below 50 when pS tone decreases in response to an increased sympathetic activity, and have been related to an analgesia/nociception imbalance [21, [33] [34] [35] [36] [37] [38] . The ANI monitor displays two values; an instantaneous values (ANIi) which represents the instantaneous response to a painful stimulus and an average ANI (ANIa) computed over 4 minutes which represent the state analgesia/nociception imbalance.
Closed-loop therapeutic devices for the anesthetized patient
Closed-loop fluid administration Automated fluid administration during surgery has been shown to be an effective tool for maintenance of a preload independent state in patients undergoing a moderate risk surgery lasting more than two hours [2] . The algorithm leading to the administration of a 100 ml bolus of fluid is based on the computed probability of response of multiple hemodynamic markers to this added plasmatic volume [3] , so that during surgery, pulse pressure variation remains below 13 % or the average cardiac index over 2.5 L.min −1 . m −2 . Interestingly, the authors infer from the results of this pilot study on a small number of cases that it could help clinicians focus on supervision of care while the repetitive and time-consuming tasks are processed by the closed-loop system [2] .
Closed-loop propofol administration
Feasibility of automated propofol administration for induction and maintenance of GA has been proven by various teams over several years now. The input signal is in all cases derived from the electroencephalographic signal (EEG), the BiSpectral Index ® (Aspect Medical Systems, MA) in some cases [9, 39, 40] , the EEG M-Entropy (GE HealthCare) [41] Technology Co., Ltd., Guangxi, China) [7] is already CE marked and commercially available. All these closed-loop controllers have been developed in order to adapt the propofol administration flow rate to obtain a target EEG index (BIS, SE or Neurosense) value around 50. They automatically adapt the propofol infusion rate proportionally to the difference between the measured EEG index and the target. All published data underline the safety of the closed-loop administration mode, and tend to demonstrate a superiority in maintaining EEG indexes in predefined target ranges when compared with manual administration (standard practice). Despite the concern expressed by some authors that EEG derived indexes of depth of hypnosis are influenced by the use of myorelaxants [45] , no clinical investigation has to our knowledge evaluated the impact of myorelaxation on closed-loop administration devices targeting specific EEG effects. Interestingly, there has been only few attempts to "close the loop" on halogenated ethers, probably because researchers have not had the opportunity to control the evaporators incorporated in anaesthesia machines [46] [47] [48] . As far as the "target signal" is concerned, propofol closed-loop devices have mainly relied on EEG derived indexes such as BiSpectral index or M-Entropy. There is only one publication reporting a propofol closed-loop system on the latency of the somatosensory evoked response of the forepaw in mice [49] .
Closed-loop myorelaxant administration
Despite well-established thresholds, a myorelaxant closedloop device has been commercialised only recently: the Concert-CL ® (Veryark ® Technology Co., Ltd., Guangxi, China) is able to administer various myorelaxant drugs by using the muscular response to electrical stimuli as target.
Its effectiveness in maintaining a suitable depth of myorelaxation and its benefit for the patient need still to be demonstrated.
Closed-loop opioid administration
During the course of GA, closing the loop on analgesia as it has been done for hypnosis and myorelaxation may further help personalize analgesia and hence reduce opioid side effects, the main problem being identifying the "right" nociceptive signal as there is no surrogate parameter for analgesia during GA [50] . Two devices have already been validated: EasyTIVA ® (Medsteer ® , Suresnes, France) [8, 9] and McSleepy ® (McGill university, Québec, Canada) [44] . The analgesic targets differ between these two devices: EasyTIVA ® targets specific changes in a EEG-derived signal that has been related to nociception during surgery under propofol anaesthesia [39] , and hence infers therapeutic changes implemented by an automated syringe pump administering a short acting opioid: remifentanil [51] . The EasyTIVA(R) continuously adapt both the propofol and remifentanil targets to obtain an error between the measured BIS and the target close to 0. The error magnitude determines the drug to modify. When the error is small, only the remifentanil flow rate is changed. When the error is important, both remifentanil and propofol are changed. On the other hand, McSleepy ® targets an Analgoscore close to 0. Changes in this score lead similarly to therapeutic adaptations implemented by an automated syringe pump administering also remifentanil. The remifentanil flow rate is adapted proportionally to the difference between the measured analog score and the target. The ANIloop [51] automatically adapts the remifentanil flow rate regarding the instantaneous and the mean values of the ANI (ANIi and ANIa). The remifentanil flow rate is asynchronously adapted in order to maintain an ANIa value between 50 and 70. On the other hand, a small bolus of remifentanil is performed when a fast decrease of ANIi is observed. device has already been extensively tested and has shown its added value in evaluating non-opioid analgesic drugs and measuring objectively the induced opioid sparing effect [43] or in specific populations where analgesic dosage is difficult, e. g. morbidly obese patients [9] . The closed-loop device for remifentanil administration developed by De Jonckheere J et al. has only been tested on a simulated environment [52] .
Evaluation of closed-loops
A recent meta-analysis by Pasin et al. has evaluated closed-loop devices for intravenous anaesthesia [53] , and concluded to the superiority of closed-loop delivery vs manual delivery (total intravenous anaesthesia: TIVA) but not vs target controlled infusion (TCI), with lower doses of propofol needed for induction and more precisely maintained BIS targets. The performance of various administration mode was assessed by the combination of the median absolute performance error and the wobble index, which were both lower in the case of closed-loop systems than with manually controlled administration of TIVA (p for effect < 0.00001 and = 0.003 resp.). The methodology for evaluating an infusion device has been paved by Varvel et al. [54] . The performance can be evaluated with the four following indicators: typical miss, divergence, bias and wobble, the basis of all being the performance error (PE):
with i: the index of the patient (i th patient) j: the index of the plasma drug concentration (j th plasmatic measurement) Cm: the measured plasmatic drug concentration Cp: the predicted plasmatic drug concentration and can be applied to any given index as follow [55] : Median Performance Error (Bias)
Wobble for the i th patient is the median absolute deviation from MDPE i wobble i = median PE ij − MDPE i , j = 1..N i Â Ã Secondary outcomes can be added to these parameters, such as drug total administered dose, number of drug administration changes and duration of time the target index spends in predetermined ranges. A recent metaanalysis by Pasin et al. used MDAPE and wobble as comparison means of various closed-loop anesthetic delivery systems, to which they added propofol total administered dose, maintenance of heart rate between 25% of baseline, maintenance of mean arterial pressure (MAP) between 25% of baseline, fall in MAP from baseline and ephedrine boluses [53] . Similarly to these adjuncts, Soltesz et Dumont proposed to add several clinically based indicators in order to characterize the quality of induction, maintenance and emergence phases of anaesthesia [56] .
Conclusion
Various closed-loop devices are entering the clinical practice of general anaesthesia, and are showing enough safety that they become acceptable in the operating room. Their benefit in terms of clinical outcomes however still needs to be demonstrated. The multiplication of closed-loop administration devices constitutes a message to practitioners for the near future that they need to understand more than the drug and the multitude of signals produced by the numerous monitors that surround routinely any patient undergoing anaesthesia: they need to understand how a controller is influenced by a signal and reacts in administering a given drug. In other words, they need to go from decision making to supervision.
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